Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Mechanism of Action

Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.

Typical Dosage (Research)

Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.

Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.

Side Effects & Risks

Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.

Same thyroid cancer warnings as GLP-1 agonists. Risk of pancreatitis, gallbladder disease, hypoglycemia when combined with insulin or sulfonylureas.

Who Uses Tirzepatide

Those seeking maximum weight loss efficacy, Type 2 diabetics, individuals who haven't achieved goals with GLP-1 monotherapy.